Ocera Therapeutics, Inc. (NASDAQ:OCRX) was the target of a large decrease in short interest during the month of October. As of October 13th, there was short interest totalling 410,544 shares, a decrease of 43.7% from the September 29th total of 728,662 shares. Based on an average daily volume of 400,728 shares, the short-interest ratio is currently 1.0 days. Currently, 1.9% of the company’s shares are short sold.

An institutional investor recently raised its position in Ocera Therapeutics stock. Virtu KCG Holdings LLC increased its holdings in Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 194.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 213,531 shares of the biopharmaceutical company’s stock after purchasing an additional 141,040 shares during the period. Virtu KCG Holdings LLC owned 0.81% of Ocera Therapeutics worth $248,000 as of its most recent SEC filing. Institutional investors and hedge funds own 20.25% of the company’s stock.

Ocera Therapeutics (NASDAQ OCRX) opened at 1.03 on Friday. The stock has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.11. The firm’s market cap is $27.31 million. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $2.95.

Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. Equities research analysts expect that Ocera Therapeutics will post ($1.20) EPS for the current year.

Separately, Zacks Investment Research raised Ocera Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $2.25.

WARNING: “Ocera Therapeutics, Inc. (OCRX) Sees Large Decline in Short Interest” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/28/ocera-therapeutics-inc-ocrx-sees-large-decline-in-short-interest.html.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.